



PROSPAN® as add-on treatment in childhood bronchial asthma

Zeil S et.al., Tolerance and effect of an add-on treatment with a cough medicine containing ivy leaves dry extract on lung function in children with bronchial asthma. *Phytomedicine* 2014; 21:1216-20.

Cross-over study design



Improvement in lung function parameters after 4 weeks' treatment



Study design: » Randomised, placebo-controlled, double-blind, cross-over

Diagnosis: » Partially uncontrolled or uncontrolled mild, persistent bronchial asthma (despite long-term treatment with 400 µg of budesonide equivalent), Stage 2 according to the criteria of the German Airway League

Study dosage: » Maintenance therapy for the whole duration of the study: 400 µg of budesonide equivalent/day.
» Add-on treatment in the form of 2 x 5 ml/day of **PROSPAN®** Cough Syrup or placebo for 28-30 days.

Results: » Significant improvements in the absolute values for the parameters MEF₇₅₋₂₅ (rise by 0.115 l/s on average, p = 0.044), MEF₂₅ (rise by 0.09 l/s on average, p = 0.041) and VC (rise by 0.052 l on average, p = 0.044) with add-on **PROSPAN®** treatment compared to placebo.
» The treatment was tolerated very well.

Conclusion: » The results of this proof-of-concept study confirm the bronchodilatory effect of **PROSPAN®** EA 575®.
» Despite regular inhalational corticoid therapy, children with mild, uncontrolled asthma may benefit from add-on treatment with **PROSPAN®** EA 575®.
» Further studies are required in order to further investigate the understanding of the benefits of add-on treatment with **PROSPAN®** EA 575® in asthma patients.